SeekIn OncoSeek Multi-Cancer Detection Test Gets CE Mark

September 16, 2022

SeekIn received a CE mark for its OncoSeek Multi-Cancer Detection Test.

The tool is a customized panel of seven protein tumor markers (PTMs) including AFP, CA125, CA15-3, CA19-9, CA72-4, CEA and CYFRA21-1, said the company. The test scrutinizes plasma levels of these PTMs and age of the subjects in order to calculate the probability of cancer index.

SeekIn said immunological measurement of blood-based tumor markers for cancer detection has significant advantages, including being non-invasive, automated, quantitative, objective, and relatively inexpensive compared with histology, endoscopy, and imaging.

With the CE mark in hand, SeekIn said it’s ready to launch the test in the European Union and other countries that recognize the CE mark.

View today's stories